title: Potential role of rilotumumab in the treatment of gastric cancer.
abstract: In 2014, outcomes for patients with advanced gastric cancer remain extremely poor with a high level of unmet need regarding effective therapeutic options. However, recent years have seen increasing interest in the role of the MET signaling pathway in this disease subtype, leading to the development and evaluation of MET-targeted therapeutics. Rilotumumab is a monoclonal antibody directed against hepatocyte growth factor, the only known ligand for the MET receptor. It is an unlicensed product which is currently undergoing evaluation in a randomized Phase III trial in 'MET-positive' gastric cancer. Here we discuss the background to the treatment of gastric cancer as well as the characteristics of rilotumumab and reported results with this agent in the trials performed to date.
authors.affiliation: Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
authors.forename: Tom
authors.initials: T
authors.lastname: Waddell
authors.forename: Sing Yu
authors.initials: SY
authors.lastname: Moorcraft
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017228:Hepatocyte Growth Factor / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D058990:Molecular Targeted Therapy; D019859:Proto-Oncogene Proteins c-met / Q000819:agonists* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000187:drug effects; D013274:Stomach Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C524459:rilotumumab; D017228:Hepatocyte Growth Factor; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met
keywords: MET-positive; biomarker; gastric/gastro-esophageal junction cancer; rilotumumab; targeted therapy